Everolimus-eluting stents in interventional cardiology

Bare metal stents have a proven safety record, but limited long-term efficacy due to in-stent restenosis. First-generation drug-eluting stents successfully countered the restenosis rate, but were hampered by concerns about their long-term safety. Second generation drug-eluting stents have combined t...

Full description

Saved in:
Bibliographic Details
Published inVascular health and risk management Vol. 8; no. default; pp. 393 - 404
Main Authors Townsend, Jacob C, Rideout, Phillip, Steinberg, Daniel H
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2012
Taylor & Francis Ltd
Dove Press
Dove Medical Press
Subjects
Angioplasty, Balloon, Coronary - adverse effects
Angioplasty, Balloon, Coronary - instrumentation
Cardiovascular Agents - administration & dosage
Cardiovascular diseases
Care and treatment
Coronary Artery Disease - therapy
Coronary Restenosis - etiology
Coronary Restenosis - prevention & control
Drug-Eluting Stents
efficacy
Everolimus
everolimus-eluting stents
Health aspects
Humans
Patient Selection
Prosthesis Design
Review
Risk Assessment
Risk Factors
safety
Sirolimus - administration & dosage
Sirolimus - analogs & derivatives
Stents
Treatment Outcome
United States
safety
everolimus-eluting stents
efficacy
Online AccessGet full text

Cover

More Information
Summary:Bare metal stents have a proven safety record, but limited long-term efficacy due to in-stent restenosis. First-generation drug-eluting stents successfully countered the restenosis rate, but were hampered by concerns about their long-term safety. Second generation drug-eluting stents have combined the low restenosis rate of the first generation with improved long-term safety. We review the evolution of drug-eluting stents with a focus on the safety, efficacy, and unique characteristics of everolimus-eluting stents.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1178-2048
1176-6344
1178-2048
DOI:10.2147/VHRM.S23388